To include your compound in the COVID-19 Resource Center, submit it here.

IMAB362: Phase II data

Top-line data from the open-label, European Phase II FAST trial in 161 patients with CLND18.2-positive advanced or recurrent gastric or gastroesophageal junction cancer who have not received previous chemotherapy showed

Read the full 300 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE